NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
12 hedge funds and large institutions have $635K invested in NRX Pharmaceuticals Warrant in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$76.2K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$40K |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$38.1K |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$34.1K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$31.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $331K | +$13K | +34,163 | New |
|
|
PAMP
2
Polar Asset Management Partners
Toronto,
Ontario, Canada
| $93K | +$76.2K | +200,000 | New |
|
|
OAM
3
Oxford Asset Management
Oxford,
United Kingdom
| $42K | +$40K | +105,000 | New |
|
|
AA
4
AQR Arbitrage
Greenwich,
Connecticut
| $40K | +$38.1K | +100,000 | New |
|
|
YCM
5
Yakira Capital Management
Westport,
Connecticut
| $38K | +$31.4K | +82,500 | New |
|
|
GCL
6
Glazer Capital LLC
New York
| $36K | +$34.1K | +89,444 | New |
|
|
PGC
7
Pacific Grove Capital
San Francisco,
California
| $20K | +$19.1K | +50,000 | New |
|
|
WRBC
8
W.R. Berkley Corp
Greenwich,
Connecticut
| $15K | +$13.9K | +36,393 | New |
|
|
DAM
9
Deltec Asset Management
New York
| $12K | +$10.8K | +28,350 | New |
|
|
HIM
10
HGC Investment Management
Toronto,
Ontario, Canada
| $4K | +$3.8K | +9,962 | New |
|
|
BCM
11
Basso Capital Management
Stamford,
Connecticut
| $4K | +$3.81K | +10,000 | New |
|
12
UBS Group
Zurich,
Switzerland
| – | +$379 | +995 | New |
|
NRXPW Hedge Fund Activity: Q4 2017 in Review
12 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q4 2017, worth a combined $635K.
Buyers outnumbered sellers: 12 funds opened new NRXPW positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $76.2K.
- 12 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $635K of NRX Pharmaceuticals Warrant stock for Q4 2017.
- 12 funds opened new NRX Pharmaceuticals Warrant positions in Q4 2017 and 0 closed out, a net change of +12 holders.
- The largest NRX Pharmaceuticals Warrant buyer in Q4 2017 was Polar Asset Management Partners, an estimated $76.2K added.
Based on aggregated 13F filings for Q4 2017.